Follow
Jonas B. Sandbrink
Title
Cited by
Cited by
Year
Understanding the effectiveness of government interventions against the resurgence of COVID-19 in Europe
M Sharma, S Mindermann, C Rogers-Smith, G Leech, B Snodin, J Ahuja, ...
Nature communications 12 (1), 5820, 2021
1652021
Mask wearing in community settings reduces SARS-CoV-2 transmission
G Leech, C Rogers-Smith, JT Monrad, JB Sandbrink, B Snodin, R Zinkov, ...
Proceedings of the National Academy of Sciences 119 (23), e2119266119, 2022
83*2022
RNA vaccines: a suitable platform for tackling emerging pandemics?
JB Sandbrink, RJ Shattock
Frontiers in Immunology 11, 608460, 2020
722020
Understanding the effectiveness of government interventions in Europe’s second wave of COVID-19
M Sharma, S Mindermann, C Rogers-Smith, G Leech, B Snodin, J Ahuja, ...
MedRxiv, 2021.03. 25.21254330, 2021
502021
Promoting versatile vaccine development for emerging pandemics
JT Monrad, JB Sandbrink, NG Cherian
npj Vaccines 6 (1), 26, 2021
342021
Altered glycolysis triggers impaired mitochondrial metabolism and mTORC1 activation in diabetic β-cells
E Haythorne, M Lloyd, J Walsby-Tickle, AI Tarasov, J Sandbrink, I Portillo, ...
Nature communications 13 (1), 6754, 2022
282022
Biosecurity in an age of open science
JA Smith, JB Sandbrink
PLoS biology 20 (4), e3001600, 2022
21*2022
Artificial intelligence and biological misuse: Differentiating risks of language models and biological design tools
JB Sandbrink
arXiv preprint arXiv:2306.13952, 2023
152023
Biosecurity risks associated with vaccine platform technologies
JB Sandbrink, GD Koblentz
Vaccine 40 (17), 2514-2523, 2022
152022
Rapid proliferation of pandemic research: implications for dual-use risks
S Musunuri, JB Sandbrink, JT Monrad, MJ Palmer, GD Koblentz
Mbio 12 (5), 10.1128/mbio. 01864-21, 2021
132021
A dataset of non-pharmaceutical interventions on SARS-CoV-2 in Europe
G Altman, J Ahuja, JT Monrad, G Dhaliwal, C Rogers-Smith, G Leech, ...
Scientific Data 9 (1), 145, 2022
102022
Protocols and risks: when less is more
J Pannu, JB Sandbrink, M Watson, MJ Palmer, DA Relman
Nature protocols 17 (1), 1-2, 2022
102022
Insidious Insights: Implications of viral vector engineering for pathogen enhancement
JB Sandbrink, EC Alley, MC Watson, GD Koblentz, KM Esvelt
Gene Therapy 30 (5), 407-410, 2023
92023
Safety and security concerns regarding transmissible vaccines
JB Sandbrink, MC Watson, AM Hebbeler, KM Esvelt
Nature Ecology & Evolution 5 (4), 405-406, 2021
92021
Differential technology development: A responsible innovation principle for navigating technology risks
J Sandbrink, H Hobbs, J Swett, A Dafoe, A Sandberg
Available at SSRN 4213670, 2022
82022
Mitigating biosecurity challenges of wildlife virus discovery
J Sandbrink, J Ahuja, J Swett, G Koblentz, C Standley
Available at SSRN 4035760, 2022
6*2022
Improved understanding of biorisk for research involving microbial modification using annotated sequences of concern
GD Godbold, FC Hewitt, AD Kappell, MB Scholz, SL Agar, TJ Treangen, ...
Frontiers in Bioengineering and Biotechnology 11, 1124100, 2023
52023
Beyond Biosecurity by Taxonomic Lists: Lessons, Challenges, and Opportunities
P Millett, T Alexanian, KR Brink, SR Carter, J Diggans, MJ Palmer, ...
Health security 21 (6), 521-529, 2023
22023
Innovate and stockpile: respiratory protection for essential workers in a catastrophic pandemic
NX Montazeri, JB Sandbrink
Health security 21 (4), 266-271, 2023
22023
Widening the framework for regulation of dual-use research in the wake of the COVID-19 pandemic
JB Sandbrink, S Musunuri, JT Monrad
22021
The system can't perform the operation now. Try again later.
Articles 1–20